Update on medical and regulatory issues pertaining to compounded and FDA-approved drugs, including hormone therapy

Conclusions: The DQSA and its reinforcement of §503A of the FDCA solidifies FDA authority to enforce FDCA provisions against compounders of CBHT. The new law may improve compliance and accreditation by the compounding industry; support state and FDA oversight; and prevent the distribution of misbranded, adulterated, or inconsistently compounded medications, and false and misleading claims, thus reducing public health risk.
Source: Menopause - Category: OBGYN Tags: Review Articles Source Type: research